During the past decade, Jüdisches Krankenhaus Berlin conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 8 clinical trials were completed, i.e. on average, 266.7% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 3 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Jüdisches Krankenhaus Berlin" #1 sponsor was "ResMed" with 3 trials, followed by "Charite University, Berlin, Germany" with 2 trials sponsored, "Genzyme, a Sanofi Company" with 2 trials sponsored, "Abbott Medical Devices" with 1 trials sponsored and "Biogen" with 1 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Jüdisches Krankenhaus Berlin" #1 collaborator was "Bayer" with 2 trials as a collaborator, "CRI-The Clinical Research Institute GmbH" with 1 trials as a collaborator, "Centre Hospitalier Universitaire de Besancon" with 1 trials as a collaborator, "Charite University, Berlin, Germany" with 1 trials as a collaborator and "Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)" with 1 trials as a collaborator. Other collaborators include 8 different institutions and companies that were collaborators in the rest 18 trials.

According to Clinical.Site data, the most researched conditions in "Jüdisches Krankenhaus Berlin" are "Heart Failure" (3 trials), "Multiple Sclerosis, Relapsing-Remitting" (3 trials), "Chronic Heart Failure" (2 trials), "Acute Coronary Syndrome" (1 trials) and "Blood Pressure" (1 trials). Many other conditions were trialed in "Jüdisches Krankenhaus Berlin" in a lesser frequency.

Most popular intervention types in "Jüdisches Krankenhaus Berlin" are "Device" (6 trials), "Drug" (4 trials), "Biological" (2 trials), "Diagnostic Test" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Interferon beta-1a" (2 trials), "Placebo" (2 trials), "Albumin (Human) 25%, United States Pharmacopeia (USP)" (1 trials), "Alemtuzumab" (1 trials) and "Alemtuzumab 12 mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "Jüdisches Krankenhaus Berlin" are 16 trials for "All" genders.

Currently, there are NaN active trials in "Jüdisches Krankenhaus Berlin". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Jüdisches Krankenhaus Berlin, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Jüdisches Krankenhaus Berlin, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 3 trials that are defined as “Not Applicable".

Jüdisches Krankenhaus Berlin has several departments that took part in Clinical trials: "Jüdisches Krankenhaus Berlin; Abteilung fur Neurologie" - 5 trials